Asmanex Inhaler Dosing Counter Issues Under Investigation By Schering
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says problem could be related to excessive force.
You may also be interested in...
Schering-Plough’s Asmanex Twisthaler Gains Pediatric Indication
The inhaled corticosteroid powder will launch for children 4-11 in the second half, Schering tells “The Pink Sheet” DAILY.
Schering-Plough’s Asmanex Twisthaler Gains Pediatric Indication
The inhaled corticosteroid powder will launch for children 4-11 in the second half, Schering tells “The Pink Sheet” DAILY.
Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD
Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.